Diagnostic yield in the clinical genetic evaluation of autism spectrum disorders

G. Bradley Schaefer, Richard E Lutz

Research output: Contribution to journalArticle

59 Citations (Scopus)

Abstract

PURPOSE: Clinical geneticists are often asked to evaluate patients with autism spectrum disorders (ASDs) in reference to questions about cause and recurrence risk. Recent advances in diagnostic testing technology have greatly increased the options available to them. It is not currently clear what the overall diagnostic yield of a battery of tests, either collectively or individually, might be. The purpose of this study was to evaluate the diagnostic yield of a stepwise approach we have implemented in our clinics. METHODS: We used a three-tiered neurogenetic evaluation scheme designed to determine the cause of ASDs in patients referred for clinical genetic consultation. We reviewed the results of our diagnostic evaluations on all patients referred with a confirmed diagnosis of autism over a 3-year period. RESULTS: By using this approach, we found an overall diagnostic yield for ASDs of more than 40%. This represents a significant increase in the diagnostic yield reported just a few years ago. CONCLUSIONS: Given the implications of these diagnoses on recurrence risk and associated medical conditions, a targeted neurogenetic evaluation of all persons with ASDs seems warranted. We discuss the issues in the future implementation of a fourth tier to the evaluation with the potential for an even higher diagnostic yield.

Original languageEnglish (US)
Pages (from-to)549-556
Number of pages8
JournalGenetics in Medicine
Volume8
Issue number9
DOIs
StatePublished - Sep 1 2006

Fingerprint

Recurrence
Autistic Disorder
Referral and Consultation
Technology
Autism Spectrum Disorder

ASJC Scopus subject areas

  • Genetics(clinical)

Cite this

Diagnostic yield in the clinical genetic evaluation of autism spectrum disorders. / Schaefer, G. Bradley; Lutz, Richard E.

In: Genetics in Medicine, Vol. 8, No. 9, 01.09.2006, p. 549-556.

Research output: Contribution to journalArticle

@article{3500240e195d4d4eba5a0313c5beb59c,
title = "Diagnostic yield in the clinical genetic evaluation of autism spectrum disorders",
abstract = "PURPOSE: Clinical geneticists are often asked to evaluate patients with autism spectrum disorders (ASDs) in reference to questions about cause and recurrence risk. Recent advances in diagnostic testing technology have greatly increased the options available to them. It is not currently clear what the overall diagnostic yield of a battery of tests, either collectively or individually, might be. The purpose of this study was to evaluate the diagnostic yield of a stepwise approach we have implemented in our clinics. METHODS: We used a three-tiered neurogenetic evaluation scheme designed to determine the cause of ASDs in patients referred for clinical genetic consultation. We reviewed the results of our diagnostic evaluations on all patients referred with a confirmed diagnosis of autism over a 3-year period. RESULTS: By using this approach, we found an overall diagnostic yield for ASDs of more than 40{\%}. This represents a significant increase in the diagnostic yield reported just a few years ago. CONCLUSIONS: Given the implications of these diagnoses on recurrence risk and associated medical conditions, a targeted neurogenetic evaluation of all persons with ASDs seems warranted. We discuss the issues in the future implementation of a fourth tier to the evaluation with the potential for an even higher diagnostic yield.",
author = "Schaefer, {G. Bradley} and Lutz, {Richard E}",
year = "2006",
month = "9",
day = "1",
doi = "10.1097/01.gim.0000237789.98842.f1",
language = "English (US)",
volume = "8",
pages = "549--556",
journal = "Genetics in Medicine",
issn = "1098-3600",
publisher = "Lippincott Williams and Wilkins",
number = "9",

}

TY - JOUR

T1 - Diagnostic yield in the clinical genetic evaluation of autism spectrum disorders

AU - Schaefer, G. Bradley

AU - Lutz, Richard E

PY - 2006/9/1

Y1 - 2006/9/1

N2 - PURPOSE: Clinical geneticists are often asked to evaluate patients with autism spectrum disorders (ASDs) in reference to questions about cause and recurrence risk. Recent advances in diagnostic testing technology have greatly increased the options available to them. It is not currently clear what the overall diagnostic yield of a battery of tests, either collectively or individually, might be. The purpose of this study was to evaluate the diagnostic yield of a stepwise approach we have implemented in our clinics. METHODS: We used a three-tiered neurogenetic evaluation scheme designed to determine the cause of ASDs in patients referred for clinical genetic consultation. We reviewed the results of our diagnostic evaluations on all patients referred with a confirmed diagnosis of autism over a 3-year period. RESULTS: By using this approach, we found an overall diagnostic yield for ASDs of more than 40%. This represents a significant increase in the diagnostic yield reported just a few years ago. CONCLUSIONS: Given the implications of these diagnoses on recurrence risk and associated medical conditions, a targeted neurogenetic evaluation of all persons with ASDs seems warranted. We discuss the issues in the future implementation of a fourth tier to the evaluation with the potential for an even higher diagnostic yield.

AB - PURPOSE: Clinical geneticists are often asked to evaluate patients with autism spectrum disorders (ASDs) in reference to questions about cause and recurrence risk. Recent advances in diagnostic testing technology have greatly increased the options available to them. It is not currently clear what the overall diagnostic yield of a battery of tests, either collectively or individually, might be. The purpose of this study was to evaluate the diagnostic yield of a stepwise approach we have implemented in our clinics. METHODS: We used a three-tiered neurogenetic evaluation scheme designed to determine the cause of ASDs in patients referred for clinical genetic consultation. We reviewed the results of our diagnostic evaluations on all patients referred with a confirmed diagnosis of autism over a 3-year period. RESULTS: By using this approach, we found an overall diagnostic yield for ASDs of more than 40%. This represents a significant increase in the diagnostic yield reported just a few years ago. CONCLUSIONS: Given the implications of these diagnoses on recurrence risk and associated medical conditions, a targeted neurogenetic evaluation of all persons with ASDs seems warranted. We discuss the issues in the future implementation of a fourth tier to the evaluation with the potential for an even higher diagnostic yield.

UR - http://www.scopus.com/inward/record.url?scp=33748742182&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33748742182&partnerID=8YFLogxK

U2 - 10.1097/01.gim.0000237789.98842.f1

DO - 10.1097/01.gim.0000237789.98842.f1

M3 - Article

C2 - 16980810

AN - SCOPUS:33748742182

VL - 8

SP - 549

EP - 556

JO - Genetics in Medicine

JF - Genetics in Medicine

SN - 1098-3600

IS - 9

ER -